Legacy Wealth Asset Management LLC Acquires 1,581 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Legacy Wealth Asset Management LLC raised its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 19.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,509 shares of the medical equipment provider’s stock after buying an additional 1,581 shares during the period. Legacy Wealth Asset Management LLC’s holdings in Lantheus were worth $592,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Tucker Asset Management LLC boosted its position in Lantheus by 239.0% during the third quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 282 shares during the period. Principal Securities Inc. bought a new stake in Lantheus during the fourth quarter valued at about $28,000. NBC Securities Inc. increased its stake in shares of Lantheus by 28.4% in the first quarter. NBC Securities Inc. now owns 863 shares of the medical equipment provider’s stock worth $53,000 after purchasing an additional 191 shares during the period. First Horizon Advisors Inc. boosted its stake in Lantheus by 103.9% during the 4th quarter. First Horizon Advisors Inc. now owns 932 shares of the medical equipment provider’s stock valued at $58,000 after purchasing an additional 475 shares during the period. Finally, Quest Partners LLC acquired a new stake in shares of Lantheus in the fourth quarter worth $101,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Insider Transactions at Lantheus

In related news, CAO Andrea Sabens sold 341 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $76.89, for a total value of $26,219.49. Following the completion of the transaction, the chief accounting officer now directly owns 62,898 shares in the company, valued at approximately $4,836,227.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Lantheus news, Director Heinz Christoph Maeusli sold 18,373 shares of the stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $79.19, for a total transaction of $1,454,957.87. Following the completion of the transaction, the director now owns 23,340 shares in the company, valued at approximately $1,848,294.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Andrea Sabens sold 341 shares of the company’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $76.89, for a total value of $26,219.49. Following the transaction, the chief accounting officer now directly owns 62,898 shares of the company’s stock, valued at $4,836,227.22. The disclosure for this sale can be found here. Insiders have sold a total of 32,269 shares of company stock valued at $2,557,300 over the last three months. 2.10% of the stock is currently owned by corporate insiders.

Lantheus Price Performance

NASDAQ:LNTH opened at $79.56 on Friday. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $91.81. The firm has a market cap of $5.51 billion, a PE ratio of 12.15 and a beta of 0.51. The company has a quick ratio of 4.55, a current ratio of 4.84 and a debt-to-equity ratio of 0.59. The company’s 50-day moving average price is $78.60 and its two-hundred day moving average price is $66.15.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.11. Lantheus had a net margin of 33.72% and a return on equity of 54.10%. The company had revenue of $369.98 million for the quarter, compared to analyst estimates of $349.46 million. On average, equities analysts anticipate that Lantheus Holdings, Inc. will post 6.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

LNTH has been the topic of several research analyst reports. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, May 3rd. B. Riley boosted their price target on Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a research note on Thursday, April 18th. Truist Financial lifted their price objective on Lantheus from $82.00 to $96.00 and gave the stock a “buy” rating in a report on Friday, May 3rd. Finally, Mizuho lifted their price target on shares of Lantheus from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, May 3rd. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $99.17.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.